A Pfizer result is unsettling the gene therapy push for Duchenne muscular dystrophy: The boys didn't improve even though a ...

A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular ...

Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary ...

Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant ...

Because sickle cell disease isn’t as progressive a disease as others that have gene therapies available, there isn’t as much ...

Doha, Qatar: Sidra Medicine's Genetic and Genomic medicine clinic is providing life-altering gene therapy for rare genetic ...

Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. | Capricor ...

Jefferies initiated coverage of Sarepta (SRPT) with a Buy rating and $165 price target Following Elevidys’ recent label expansion in Duchenne muscular dystrophy neuromuscular disease, doctor checks ...

Wave Life Sciences (NASDAQ:WVE) is developing a treatment for Duchenne Muscular Dystrophy ... in exon 53 of the dystrophin gene. It is a type of gene therapy that aims to restore the production ...